

## 2021 Quick Reference Guide –The Vertiflex<sup>™</sup> Procedure<sup>†</sup> Physician Reimbursement

## CY 2021Medicare Physician Payments for Interspinous Spacers

CPT <sup>1,2</sup>	Description	Global Period	Total RVU³	Non-Facility National Average Payment <sup>4</sup>	Facility National Average Payment <sup>4</sup>
Interspinous Spacer Coding					
22869	Insertion of interlaminar/interspinous process stabilization/distraction device, without open decompression or fusion, including image guidance when performed, lumbar; single level	90	13.09 (Facility)	N/A	\$424
(+) 22870	Insertion of interlaminar/interspinous process stabilization/distraction device, without open decompression or fusion, including image guidance when performed, lumbar; second level	ZZZ <sup>5</sup>	3.57 <b>(Facility)</b>	N/A	\$116

## ICD-10-CM Diagnosis Code<sup>6</sup>

M48.062 Spinal stenosis, lumbar region with neurogenic claudication

Indications for Use: The Superion™ Indirect Decompression System (IDS) is indicated to treat skeletally mature patients suffering from pain, numbness, and/or cramping in the legs (neurogenic intermittent claudication) secondary to a diagnosis of moderate degenerative lumbar spinal stenosis, with or without Grade 1 spondylolisthesis, having radiographic evidence of thickened ligamentum flavum, narrowed lateral recess, and/or central canal or foraminal narrowing. The Superion™ Interspinous Spacer is indicated for those patients with impaired physical function who experience relief in flexion from symptoms of leg/buttock/groin pain, with or without back pain, who have undergone at least 6 months of non-operative treatment. The Superion Interspinous Spacer may be implanted at one or two adjacent lumbar levels in patients in whom treatment is indicated at no more than two levels, from L1 to L5. Contraindications, warnings, precautions, side effects. The Superion Indirect Decompression System (IDS) is contraindicated for patients who: have spinal anatomy that prevent implantation of the device or cause the device to be unstable in situ (i.e., degenerative spondylolisthesis greater than grade 1), Cauda equina syndrome, or prior decompression or fusion at the index level. Refer to the Instructions for Use provided on www.vertiflex.com for additional Indications for Use, contraindications information and potential adverse effects, warnings, and precautions prior to using this product. Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.

Disclaimer: Health economic and reimbursement information provided by Boston Scientific Corporation is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice. Boston Scientific encourages providers to submit accurate and appropriate claims for services. It is always the provider's responsibility to determine medical necessity, the proper site for delivery of any services and to submit appropriate codes, charges, and modifiers for services that are rendered. Boston Scientific recommends that you consult with your payers, reimbursement specialists and/or legal counsel regarding coding, coverage and reimbursement matters. Boston Scientific does not promote the use of its products outside their FDA-approved label. Information included herein is current as of November 2020, but is subject to change without notice. Rates for services are effective January 1, 2021.

Sequestration Disclaimer: Rates referenced in these guides do not reflect Sequestration; automatic reductions in federal spending that will result in a 2% across-the-board reduction to ALL Medicare rates as of January 1, 2021. (Budget Control Act of 2011)

 $^{\dagger}$ Superion<sup>™</sup> Indirect Decompression System

- 1. CPT Copyright 2020 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association. Applicable FARS/DFARS Restrictions Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
- 2. Multiple procedure reduction rules apply for procedures (excluding programming codes). Quantity of devices used in each procedure must be specified for appropriate payment. Payment rates provided are Medicare national average rates for each specified procedure with quantity = 1.
- Department of Health and Human Services. Centers for Medicare and Medicaid Services. The 2021 National Average Medicare physician
  payment rates have been calculated using a revised 2020 conversion factor of 36.0896 which reflects changes effective as of calendar year 2021.
- 4. "National Average Payment" is the amount Medicare determines to be the maximum allowance for any Medicare covered procedure. These are national average payment amounts, individual payments may vary based on locality and Medicare's geographic adjustments. Actual payment will vary based on the maximum allowance less any applicable deductibles, co-insurance etc.
- 5. ZZZ: Add-on code that you must bill with another service. No post-operative work included
- 6. ICD-10-CM Expert for Physicians: The Complete Official Code Set. Optum360, 2020.



Advancing science for life™

Neuromodulation 25155 Rye Canyon Loop Valencia, CA 91355 www.bostonscientific.com

©2021 Boston Scientific Corporation or its affiliates. All rights reserved.

NM-734304-AC